Apresitentan (Tryvio) Market Trends and Price 2025

The main indication of Aprocitentan-Tryvio is for the treatment of uncontrolled hypertension in adults, especially for patients whose blood pressure cannot be adequately controlled using conventional antihypertensive drugs (such as ACE inhibitors, ARBs, diuretics, calcium channel blockers, etc.). Studies have shown that aprecitentan can be used in combination with other antihypertensive drugs to effectively reduce blood pressure levels in patients with resistant hypertension. Reaching blood pressure targets is not only a numerical reduction, but can also significantly reduce the risk of fatal and non-fatal cardiovascular events, including stroke, myocardial infarction, and the progression of heart failure. Therefore, the application value of aprexitentan is that it provides a new treatment option for people whose long-term blood pressure is difficult to control.

In overseas markets, the original drug of Aprecitentan has begun to be sold, with a specification of 12.5 mg 30 tablets. According to recent market information, the price per box is approximately US$800, and the price may fluctuate due to exchange rate fluctuations. In some areas, generic versions have also appeared. For example, generic drugs have been officially launched in the Laos market, with the same specifications of 12.5 mg and 30 tablets, and each box sells for about 600 yuan. This provides some patients with a more cost-effective option and lays the foundation for future popularization.

In the domestic market, aprecitentan is not yet available on the market, so if patients have clinical needs, they usually need to obtain the drug through formal overseas channels. If it can enter the Chinese market and be included in the medical insurance directory in the future, its popularity will increase significantly. From the perspective of global treatment trends, the treatment of hypertension is gradually shifting to precise management of multiple mechanisms, and aprecitentan is an important drug to fill this need. It not only reflects the innovative direction of the new generation of antihypertensive drugs, but also reflects the pharmaceutical industry's research and development breakthroughs in the cardiovascular field.

Reference materials:https://go.drugbank.com/drugs/DB15059